Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | IAPP | P10997 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24090396 | 0.95 | TRPV1 (0.62) | ALDH1A1TRPV1FAAHMMEACE | |
| SCHEMBL8257309 | 0.95 | TRPV1 (0.62) | ALDH1A1TRPV1FAAHMMEACE | |
| SCHEMBL18619736 | 0.92 | MME (0.56) | ALDH1A1FAAHMMEACEITGB3 | |
| SCHEMBL20414922 | 0.88 | FAAH (0.69) | ALDH1A1TRPV1FAAHITGB3ITGA2B | |
| SCHEMBL10099813 | 0.86 | CA1 (0.56) | MMEACEITGB3ITGA2BCA1 | |
| SCHEMBL4581635 | 0.86 | FAAH (0.59) | ALDH1A1FAAHMMEACEITGB3 | |
| SCHEMBL4581634 | 0.86 | FAAH (0.59) | ALDH1A1FAAHMMEACEITGB3 | |
| SCHEMBL4179518 | 0.86 | MME (0.58) | ALDH1A1MMEACECA1CA2 | |
| SCHEMBL4179516 | 0.86 | MME (0.58) | ALDH1A1MMEACECA1CA2 | |
| SCHEMBL29926699 | 0.85 | KDM6B (0.51) | ALDH1A1TRPV1MMEACECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722923-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-05-13 | — | — | US | disclosed |
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | BAR-ILAN UNIVERSITY (IL) | 2012-11-01 | — | — | US | disclosed |
| US-8207369-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-06-26 | — | — | US | disclosed |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, GABRB2, SLC6A13 | ALDH1A1 518/4885TRPV1 4408/4885FAAH 1711/4885 |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, SNCA, SLC6A13 | ALDH1A1 684/4885TRPV1 4556/4885FAAH 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.